What is the role of molecular testing in the workup of non–small cell lung cancer (NSCLC)?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

Molecular testing forms an important part of the full pathologic evaluation of patients with metastatic non–small cell lung cancer (NSCLC). This includes testing for epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) mutation. Such testing is indicated because very effective, less toxic targeted treatments are available for patients with EGFR and ALK mutations.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!